Aurealis Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Aurealis Therapeutics is a private, clinical-stage biotech leveraging a proprietary 4-in-1 multi-target cell and gene therapy platform. Its lead program, AUP-16, has shown promising Phase 2 results in diabetic foot ulcers, tripling complete wound closure rates. The company is advancing this program while also developing an oncology candidate, AUP-55, and has recently secured CHF 8 million in funding to support its clinical pipeline.

Chronic WoundsOncologyInflammatory Diseases

Technology Platform

A 4-in-1 multi-target cell and gene therapy platform using genetically engineered lactic acid bacteria (Lactococcus lactis) as live bioreactors to deliver a combination of human therapeutic proteins to modulate the tissue microenvironment.

Opportunities

The large and growing global market for diabetic foot ulcer treatments, with limited effective therapies, presents a major commercial opportunity for AUP-16.

The platform's ability to modulate the tumor microenvironment also creates significant potential in oncology, either as a monotherapy or in combination with existing immunotherapies for hard-to-treat solid tumors.

Risk Factors

Key risks include clinical trial failure in upcoming Phase 3 studies for AUP-16, regulatory challenges associated with a novel genetically modified bacterial therapy, and intense competition in both the advanced wound care and immuno-oncology spaces.

The company also faces financial risk as a pre-revenue entity dependent on investor funding.

Competitive Landscape

In chronic wounds, Aurealis competes with companies developing advanced biologics, skin substitutes, and other cell therapies. In oncology, it faces competition from numerous firms developing microenvironment-targeting therapies and next-generation immunotherapies. Its key differentiator is its unique 4-in-1 multi-target approach using a scalable bacterial delivery system.

More companies in Cell & Gene Therapy →More companies in Switzerland →